Post hoc analysis of 1,052 men with metastatic castration-sensitive prostate cancer in TITAN: combining CHAARTED and LATITUDE criteria better predicted survival (C-index 0.645 vs 0.628 and 0.621). Apalutamide showed no clear benefit in double low synchronous disease.
Secondary analysisn = 1,052
Hori et al. Integrating NCCN and LATITUDE in metastatic castration-sensitive prostate cancer: a TITAN analysis